GO
Loading...

Biotechnology

More

  • ASCO cancer care conference kicks off     Friday, 30 May 2014 | 1:01 PM ET

    In the U.S., half of all men and a third of all women will develop cancer in their lifetimes. CNBC's Meg Tirrell reports which stocks analysts are eyeing into the conference.

  • War on cancer     Thursday, 29 May 2014 | 1:38 PM ET

    The big topic at this year's cancer care conference ASCO will be immunotherapy drugs. CNBC's Meg Tirrell explains how these drugs work.

  • Valeant raises Allergan bid     Wednesday, 28 May 2014 | 10:54 AM ET

    Valeant is upping its offer for Allergan in a proposal that could now be worth more than $50 billion, reports CNBC's Meg Tirrell.

  • Why Mesoblast is big on stem-cell therapy     Tuesday, 27 May 2014 | 11:38 PM ET

    Silviu Itescu, CEO of Mesoblast, highlights sources of growth that may propel stem-cell therapy into a multi billion-dollar market by 2020.

  • How not to fear biotech     Thursday, 15 May 2014 | 1:24 PM ET

    Discussing hot picks in the biotech space, with Matthew Roden, UBS executive director.

  • May 14- Prima BioMed Ltd said its experimental lead treatment improved survival in some ovarian cancer patients without the disease worsening. CVac, like Dendreon Corp's prostate cancer vaccine Provenge, is a form of immunotherapy that stimulates the patient's immune system to target and destroy tumors.

  • Big gains for Nasdaq     Monday, 12 May 2014 | 11:59 AM ET

    CNBC's Seema Mody reveals what stocks and sectors are driving the Nasdaq rally today.

  • CNBC's Meg Tirrell speaks to Ken Frazier, Merck chaiman & CEO, about selling the company's consumer unit to Bayer. Frazier also gives his stance on mega-mergers and U.S corporate tax rate.

  • 'Super bug' spreads     Monday, 5 May 2014 | 1:32 PM ET

    CNBC's Meg Tirrell reports the World Health Organization has confirmed about 262 cases of the MERS virus, of which 93 people have died. Dr. William Schaffner of the Vanderbilt School of Medicine, provides insight.

  • End-game of polio 'fragile': Expert     Monday, 5 May 2014 | 1:32 PM ET

    Dr. William Schaffner of the Vanderbilt School of Medicine, addresses the latest polio outbreaks, and the importance of vaccinating children.

  • Is Apple hiring spree a sign new device is coming? Monday, 5 May 2014 | 11:28 AM ET
    Apple CEO Tim Cook looks on at an Apple Store on September 20, 2013 in Palo Alto, California.

    Apple is expanding to medical technology. The company is recruiting a team of medical executives and has offered hints of the iWatch and others.

  • AstraZeneca rejects new Pfizer bid     Friday, 2 May 2014 | 9:07 AM ET

    AstraZeneca has rejected Pfizer's sweetened bid claiming it undervalues the company. The "Squawk on the Street" news team shares their thoughts on the latest bid and the U.S. tax code.

  • Cramer: Pfizer solution loved by market     Tuesday, 29 Apr 2014 | 9:07 AM ET

    The "Squawk on the Street" news team break down Merck's quarterly earnings beat and discuss the state of big pharma and taxes.

  • Pfizer, AstraZeneca about drug pipeline: Pro     Monday, 28 Apr 2014 | 11:23 AM ET

    Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.

  • Pfizer is working on its next move in a potential $100 billion battle for AstraZeneca after having two bids rejected. CNBC's Meg Tirrell reports buying AstraZeneca would boost Pfizer's cancer drug pipeline.

  • April 28- Athersys Inc said its experimental stem-cell therapy for treating an inflammatory bowel disease failed to show any meaningful benefit in early results from a trial, sending its shares plunging 57 percent before the bell.

  • The trial, conducted by Athersys's partner Pfizer Inc, did not show a statistically significant reduction in the severity of the disease and rectal bleeding as compared to placebo.

  • Analyst suggests Allergan buy Shire     Thursday, 24 Apr 2014 | 12:41 PM ET

    CNBC's Meg Tirrell reports a Cowen analyst is suggesting Allergan buy ADHD drug maker Shire. The FMHR traders, provide perspective.

  • Biogen barreling down on Alzheimer's     Wednesday, 23 Apr 2014 | 3:33 PM ET

    CNBC's Meg Tirrell speaks with George Scangos, Biogen Idec CEO, about the drug maker's fight against MS and Alzheimer's. Scangos also comments on Valeant's bid for Alllergan.

  • Tech & biotech plays for your portfolio     Wednesday, 23 Apr 2014 | 10:04 AM ET

    Kevin Caron, Stifel Private Client Group market strategist, and Doug MacKay, Broadleaf Partners president & CIO, discuss signs of a tech bubble and share their investment strategies on hot technology stocks.